Hi [[ session.user.profile.firstName ]]

Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers

Join us for the March CDx Insights webinar “Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers.” Our speaker is Yaso Natkunam, MD, PhD, Professor of Pathology and Director of Hematopathology at Stanford University School of Medicine. Dr Natkunam will review key updates to the classifications of large B-cell lymphomas in the “2016 revision of the World Health Organization classification of lymphoid neoplasms.” She will also discuss the role of diagnostic and predictive biomarkers in DLBCL, high grade B-cell lymphoma and other large B-cell lymphomas.
Recorded Mar 29 2017 58 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Yaso Natkunam, MD, PhD, Professor of Pathology, Director of Hematopathology, Stanford University School of Medicine
Presentation preview: Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • Diagnostic Methods for High Grade (Less Favorable) Malignant Lymphomas Jun 8 2021 3:00 pm UTC 60 mins
    Dr. Peter Banks, Consultant Pathologist at Roche Tissue Diagnostics
    Join us as Dr. Peter Banks, Consultant Pathologist at Roche Tissue Diagnostics, presents part 3 in this 3 part series on malignant lymphomas. High grade lymphomas can arise at any age, including childhood. Advances in our understanding of these neoplasms allow precise classification and, in most cases today, the possibility of cure. Methods for classification and recognition of these malignancies, as distinct from other forms of aggressive cancer, are demonstrated with the use of cases selected on the basis of their educational merit.
  • Diagnostic Methods for Low Grade (More Favorable) Malignant Lymphomas May 25 2021 3:00 pm UTC 60 mins
    Dr. Peter Banks, Consultant Pathologist at Roche Tissue Diagnostics
    Join us as Dr. Peter Banks, Consultant Pathologist at Roche Tissue Diagnostics, presents part 2 of 3 in this series on malignant lymphomas. Low grade lymphomas are slowly progressive neoplasms most typically arising in older patients. They are usually highly sensitive to conventional modes of therapy but can progress into aggressive lethal forms. Usually presenting in an advanced stage, these diseases are difficult to totally eradicate. For the pathologist the critical distinction between lymphoma and benign immune reaction can be difficult, requiring the application of special studies, in particular immunohistochemistry and genetic clonal determination. Case examples representing the commonest differential diagnostic challenges are illustrated.
  • Our Scientific Understanding of Malignant Lymphomas May 18 2021 3:00 pm UTC 60 mins
    Dr. Peter Banks, Consultant Pathologist at Roche Tissue Diagnostics
    Join us as Dr. Peter Banks, Consultant Pathologist at Roche Tissue Diagnostics, will be presenting a 3 part series on malignant lymphomas. The field of hematopathology has long served as a vanguard for conceptual advances in our understanding of malignancies. Part one of this series traces the sometimes unlikely succession of critical scientific breakthroughs: from Hodgkin’s proposal in 1832 that malignancies could originate in organs of the immune system, to the discovery of the Philadelphia chromosome, to methods relating these neoplasms to their counterpart elements in the immune system, to the implications of genetically determined proliferation pathways. This presentation serves as a foundation for the following two, which deal with the specifics of diagnosing lymphomas.
  • NTRK gene fusions in solid tumors: IHC and molecular testing strategies May 12 2021 3:00 pm UTC 60 mins
    Caterina Marchiò, MD, PhD and Reinhard Büttner, MD
    In this webinar Drs. Marchiò and Büttner will review the role of NTRK gene fusions in solid tumors, with an in-depth look at IHC and molecular methods of testing. Dr. Marchiò will discuss some specific IHC staining examples and how to interpret them; while Dr. Büttner will provide insight on molecular testing considerations with strengths and weaknesses. This webinar will provide an expert look into the NTRK testing landscape with an opportunity for questions and discussion.
  • Artificial Intelligence in Clinical Digital Pathology Recorded: Dec 16 2020 61 mins
    Joachim Schmid, Dr. Uwe Horchner, and Dr. Christoph Guetter of the Digital Pathology team at Roche Tissue Diagnostics
    In this webinar, Joachim Schmid, PhD, VP Research & Development, Dr. Uwe Horchner, Principal Scientist and Dr. Christoph Guetter, Senior Manager, Tissue Image Analysis, will provide an understanding of the differences between research and clinical artificial intelligence (AI)-based digital pathology algorithms; to illustrate the various important aspects for AI algorithm development for IVD; and to describe the challenges with implementing standards of interoperability. This comprises Roche’s holistic approach to AI-driven image analysis algorithms for use in clinical digital pathology.
  • Key Notables on IHC Interpretation of PD-L1 SP263 on FNA samples Recorded: Dec 15 2020 40 mins
    Dr. Dorothy Hayden, Pathologist, Companion Diagnostic, at Roche Tissue Diagnostics
    Dr. Dorothy Hayden, Staff Pathologist, Companion Diagnostics with Roche Tissue Diagnostics, will discuss key insights that can be applied to successful staining and interpretation of Fine Needle Aspiration (FNA) samples with the VENTANA PD-L1(SP263) Assay. FNA is a commonly used procedure for obtaining pathology samples and is often used to collect samples of Non-Small Cell Lung Cancer (NSCLC). Considerations should be made in sample preparation, staining, and evaluation when FNAs are stained with immunohistochemical biomarkers for diagnostic and predictive purposes.
  • Validation of Low Prevalence Biomarkers in the Laboratory Recorded: Dec 9 2020 76 mins
    Dr. Dylan Miller, University of Utah, Utah USA and Dr. Emina Torlakovic, University of Saskatchewan, Saskatoon, SK Canada
    In this BrightTALK webinar, Dr. Dylan Miller and Dr. Emina Torlakovic will discuss approaches and perspectives on validation of low prevalence biomarkers in the laboratory. Dr. Miller will share from his experiences and discuss the application of principles based on the Center Guidelines from the College of American Pathologists (CAP). Dr. Torlakovic will share examples of real world validation of low prevalence biomarkers. Both speakers will help a laboratory understand what they should expect when validating low prevalence biomarkers and will highlight points to consider when approaching these validations.
  • Optimize Patient Outcomes by Improving Pre-Analytics Recorded: Nov 17 2020 60 mins
    Dr. David Hicks, Prof & Dir of IHC-ISH Laboratory & Breast Subspecialty Service, University of Rochester Medical Center
    With the increasing emphasis on precision medicine in oncology and the need for biomarker testing, pathologists and the pathology community are in the center of the patient's tissue journey. As guardians and stewards of the tissue, pathologists are responsible for ensuring the quality of samples used for accurate diagnosis and biomarker testing. Preanalytics - the collection, handling and processing of clinical biospecimens - are critically important but rigor around the control of factors that adversely affect biospecimens is lacking. This presentation will introduce the tissue optimization and pre-analytic standardization program developed by APPIA, the Anatomic Pathology Patient Interest Association, a non-profit consortium with membership from Agilent, Leica Biosystems, Roche and Sakura Finetek. The mission of APPIA is to advance patient safety, quality, standards and accessibility of care in anatomic pathology. This presentation will provide a better understanding of how the lack of standardization of pre-analytic factors has the potential to negatively impact the quality of the tissue specimen for downstream diagnostic and molecular testing. Examples of best practices to help optimize tissue preservation and quality and how these can be implemented in clinical practice will be discussed.
  • Demystifying Cancer Immunology Recorded: Oct 22 2020 61 mins
    Dr. Josef Kurtz, Professor of Biology, Chief Academic Officer at Emmanuel College in Boston, MA
    The interplay between the immune system and cancer remains one of the biggest enigmas and opportunities in medicine. During this webinar, we will review the basic tenants of how the immune system is organized and functions, as well as the major components (antibodies, T cells, signaling pathways, etc.). The goal of this webinar is to better understand how a system so exquisitely tuned and effective in defending our bodies from pathogens can be so challenged when the disease is of our own cells.
  • Computational Pathology & Quantitative Biomarkers of the Tumor Microenvironment Recorded: Oct 15 2020 59 mins
    Dr. Lee Cooper, Associate Professor of Pathology, Northwestern University Feinberg School of Medicine
    Computational pathology tools can aid in deciphering features of the tumor microenvironment in whole-slide images of cancer specimens. Digital pathology will generate petabytes of data over the coming decade, and quantitative and high-resolution descriptions of tissue morphology linked with clinical and genomic data can help to inform diagnostic criteria and advance understanding of disease and treatment. This talk will describe development of machine learning tools for dense high-resolution mapping of tissue components, including the generation of data for training and validation, and will discuss implications for the future practice of pathology and research.
  • Digital Pathology: Current and Future Benefits Using PD-L1 as the Paradigm Recorded: Aug 27 2020 60 mins
    Dr. Alex Haragan, Pathologist MRC Clinical Research Fellow at Royal Liverpool University Hospital, Liverpool, England
    This webinar will give an overview of the Roche uPath software with particular regards to digital slide image viewing and the use of the PD-L1 immunohistochemistry interpretation algorithm. The pros and cons of digital pathology and uPath will be considered, with a focus on the use of the PD-L1 algorithm and how this can be used to augment pathologists' ability to interpret this tricky predictive biomarker in the context of NSCLC.
  • Module 3: Ventana PD-L1 (SP263) Assay NSCLC Guided Digital Case Review Recorded: Jul 24 2020 71 mins
    Dr. Dorothy Hayden, Pathologist at Roche Tissue Diagnostics
    This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell lung cancer (NSCLC).

    Please refer to the respective drug labeling for clinical recommendations pertaining to PD-L1 expression.

    These videos feature Roche Tissue Diagnostics Pathologist, Dr. Dorothy Hayden, and are intended to be a refresher for pathologists and laboratories on VENTANA PD-L1 (SP263) Assay in NSCLC. Module 1 is a PD-L1 and PD-L1 (SP263) assay overview , Module 2 discusses evaluation guidance for PD-L1 (SP263) assay in NSCLC, and Module 3 is a PD-L1 (SP263) Guided Digital NSCLC Case Review.
  • Module 2: Ventana PD-L1 (SP263) Assay NSCLC Evaluation Education Recorded: Jul 24 2020 18 mins
    Dr. Dorothy Hayden, Pathologist at Roche Tissue Diagnostics
    This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell lung cancer (NSCLC).

    Please refer to the respective drug labeling for clinical recommendations pertaining to PD-L1 expression.

    These videos feature Roche Tissue Diagnostics Pathologist, Dr. Dorothy Hayden, and are intended to be a refresher for pathologists and laboratories on VENTANA PD-L1 (SP263) Assay in NSCLC. Module 1 is a PD-L1 and PD-L1 (SP263) assay overview , Module 2 discusses evaluation guidance for PD-L1 (SP263) assay in NSCLC, and Module 3 is a PD-L1 (SP263) Guided Digital NSCLC Case Review.
  • Module 1: Ventana PD-L1 (SP263) NSCLC Assay Overview Recorded: Jul 24 2020 11 mins
    Dr. Dorothy Hayden, Pathologist at Roche Tissue Diagnostics
    This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell lung cancer (NSCLC).

    Please refer to the respective drug labeling for clinical recommendations pertaining to PD-L1 expression.

    These videos feature Roche Tissue Diagnostics Pathologist, Dr. Dorothy Hayden, and are intended to be a refresher for pathologists and laboratories on VENTANA PD-L1 (SP263) Assay in NSCLC. Module 1 is a PD-L1 and PD-L1 (SP263) assay overview , Module 2 discusses evaluation guidance for PD-L1 (SP263) assay in NSCLC, and Module 3 is a PD-L1 (SP263) Guided Digital NSCLC Case Review.
  • The Pathologist in the Era of Immunotherapy Recorded: Jul 23 2020 61 mins
    Dr. Ken Bloom
    The job of the pathologist is crucial in the era of precision medicine and immunotherapy. Pathologists need not only to correctly diagnose and classify tumors, but also aid in the selection of the best treatment strategies based on the presence or absence of critical biomarkers. Because tumors are heterogeneous, this includes discussion with the interventionalist about which lesions to sample in metastatic disease and selection of the best area of tumor for analysis in resections. While next generation sequencing techniques provide a plethora of data about mutations, gene expression and copy number, the pathologist must interpret these results in the context of the histologic appearance of the sample. In this webinar, Dr. Bloom will review the challenges faced by pathologists today with the emergence of immunotherapy and explain the critical role of the pathologist in assessing the tumor and its microenvironment.
  • Breast Cancer Diagnostics Practical Considerations and What's On the Horizon Recorded: Jul 16 2020 62 mins
    Dr. Sunil Badve
    Breast cancer is the most commonly occurring cancer in women with over two-million newly diagnosed patients worldwide in 2018. At the molecular level, breast cancer is a heterogeneous disease. Precision medicine and targeted therapies have a long history in the diagnosis and treatment of breast cancer. Early-stage breast cancer is now a curable disease in the majority of patients but advanced breast cancer remains largely incurable. The identification of new actionable targets continues to drive the development of innovative therapeutic approaches in breast cancer. This webinar will review a series of three breast cancer patients providing a practical approach to diagnostic testing and share perspectives on future testing options and precision pathology.
  • Lung Cancer Diagnostics: Evolving Practice and Future Directions Recorded: May 21 2020 61 mins
    Professor Keith Kerr
    Personalized medicine for non-small-cell lung cancer (NSCLC) continues to evolve rapidly, building on a solid diagnostic foundation based on H&E and immunohistochemistry (IHC), incorporating predictive biomarker testing for oncogene-directed therapies and immunotherapies. Understanding the role of biomarker testing, different technologies and latest developments is vitally important for practicing pathologists.

    During this Bright TALK webinar, Professor Keith Kerr will review the current diagnostic pathways in lung cancer, outline the role of IHC and molecular testing, differentiate oncogene biomarkers from immunotherapy biomarkers, and share his perspectives on future directions in lung cancer testing, including multiplexed assays.
  • Understanding genome-wide NIPT Recorded: May 12 2020 57 mins
    Dr. Liza Kunz and Jen Kaplan, LCGC
    Cell-free DNA prenatal test menus have rapidly expanded in recent years to address not only the common trisomies, but also sex chromosome aneuploidies, copy number variants, and rare autosomal trisomies. However, “more” is not necessarily “better”. Potential benefits to patients must be carefully weighed against potential harms before tests are introduced into clinical practice. Please join us for an in-depth examination of clinical considerations and implications of expanded cfDNA test menus.
  • Clinical decision support in the NGS Oncology workflow Recorded: May 7 2020 56 mins
    Dr. Stephanie Yaung
    The increasing adoption of next generation sequencing (NGS) in molecular profiling of cancer presents a need for streamlined result interpretation in clinical labs. With growing complexity of NGS results, evolving guidelines, and fragmented data sources, clinical decision support (CDS) systems can facilitate reporting of clinically relevant variants. In this talk, our speaker will discuss how software capable of automatically interpreting and presenting clinically relevant information reduces the need for time-consuming and error-prone manual curation.
  • OMG Twins? NIPT for multiple pregnancy Recorded: Apr 30 2020 49 mins
    Renee Jones, LCGC
    Pregnancies with more than one fetus are not uncommon. cfDNA analysis of twin pregnancies is confounded by unique technical and biological factors. This talk will review published data for the prenatal use of cfDNA analysis in twin pregnancies and highlight clinical considerations that influence the use of this approach for aneuploidy risk assessment.
DIASights from Roche
This series is brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers
  • Live at: Mar 29 2017 4:00 pm
  • Presented by: Yaso Natkunam, MD, PhD, Professor of Pathology, Director of Hematopathology, Stanford University School of Medicine
  • From:
Your email has been sent.
or close